JP2024543505A5 - - Google Patents
Info
- Publication number
- JP2024543505A5 JP2024543505A5 JP2024529127A JP2024529127A JP2024543505A5 JP 2024543505 A5 JP2024543505 A5 JP 2024543505A5 JP 2024529127 A JP2024529127 A JP 2024529127A JP 2024529127 A JP2024529127 A JP 2024529127A JP 2024543505 A5 JP2024543505 A5 JP 2024543505A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- pharmaceutical composition
- less
- composition according
- aqueous pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163264132P | 2021-11-16 | 2021-11-16 | |
| US63/264,132 | 2021-11-16 | ||
| PCT/GB2022/052903 WO2023089308A1 (en) | 2021-11-16 | 2022-11-16 | Methods for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024543505A JP2024543505A (ja) | 2024-11-21 |
| JP2024543505A5 true JP2024543505A5 (https=) | 2025-11-26 |
Family
ID=84535807
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024529127A Pending JP2024543505A (ja) | 2021-11-16 | 2022-11-16 | 癌の治療方法 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4433025A1 (https=) |
| JP (1) | JP2024543505A (https=) |
| KR (1) | KR20240100420A (https=) |
| CN (1) | CN118475345A (https=) |
| AU (1) | AU2022390670A1 (https=) |
| CA (1) | CA3237681A1 (https=) |
| IL (1) | IL312680A (https=) |
| MX (1) | MX2024005855A (https=) |
| WO (1) | WO2023089308A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107148425B (zh) | 2014-10-29 | 2021-08-03 | 拜斯科阿迪有限公司 | 对mt1-mmp特异性的双环肽配体 |
| EP3645549A1 (en) | 2017-06-26 | 2020-05-06 | BicycleRD Limited | Bicyclic peptide ligands with detectable moieties and uses thereof |
| JP7670481B2 (ja) | 2017-08-04 | 2025-04-30 | バイスクルテクス・リミテッド | Ｃｄ１３７に対して特異的な二環式ペプチドリガンド |
| CN111902429A (zh) | 2018-02-23 | 2020-11-06 | 拜斯科技术开发有限公司 | 多聚体双环肽配体 |
| IL279489B2 (en) | 2018-06-22 | 2025-10-01 | Bicycletx Ltd | Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate |
| GB201820325D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for psma |
| GB201820288D0 (en) | 2018-12-13 | 2019-01-30 | Bicycle Tx Ltd | Bicycle peptide ligaands specific for MT1-MMP |
| GB201820295D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for MT1-MMP |
| WO2020128527A1 (en) | 2018-12-21 | 2020-06-25 | Bicyclerd Limited | Bicyclic peptide ligands specific for pd-l1 |
| US12492224B2 (en) | 2018-12-21 | 2025-12-09 | Bicycletx Limited | Bicyclic peptide ligands specific for PD-L1 |
| GB201900529D0 (en) | 2019-01-15 | 2019-03-06 | Bicycletx Ltd | Bicyclic peptide ligands specific for CD38 |
| TWI860386B (zh) | 2019-07-30 | 2024-11-01 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
| AU2021322934A1 (en) | 2020-08-03 | 2023-03-30 | Bicycletx Limited | Peptide-based linkers |
| WO2025125648A1 (en) | 2023-12-13 | 2025-06-19 | Bicycletx Limited | Bicyclic peptide complex for use in treating cancer |
| WO2025125652A1 (en) * | 2023-12-13 | 2025-06-19 | Bicycletx Limited | Combination therapy for use in treating cancer |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI860386B (zh) * | 2019-07-30 | 2024-11-01 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
-
2022
- 2022-11-16 KR KR1020247019471A patent/KR20240100420A/ko active Pending
- 2022-11-16 CA CA3237681A patent/CA3237681A1/en active Pending
- 2022-11-16 WO PCT/GB2022/052903 patent/WO2023089308A1/en not_active Ceased
- 2022-11-16 EP EP22823612.1A patent/EP4433025A1/en active Pending
- 2022-11-16 IL IL312680A patent/IL312680A/en unknown
- 2022-11-16 CN CN202280086394.XA patent/CN118475345A/zh active Pending
- 2022-11-16 MX MX2024005855A patent/MX2024005855A/es unknown
- 2022-11-16 AU AU2022390670A patent/AU2022390670A1/en active Pending
- 2022-11-16 JP JP2024529127A patent/JP2024543505A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024543505A5 (https=) | ||
| JP2023505756A5 (https=) | ||
| JP2023526451A5 (https=) | ||
| CN1140272C (zh) | 抗肿瘤剂 | |
| JP2022121594A5 (https=) | ||
| KR102265952B1 (ko) | 암 치료 병용요법으로서 에리불린 및 렌바티닙의 용도 | |
| US20170100368A1 (en) | Use of eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer | |
| JP2022031331A (ja) | 空間配置が変化した組換えインターフェロンを用いる腫瘍治療の方法 | |
| WO2007095850A1 (en) | A pharmaceutical composition of docetaxel, preparation and use | |
| CN103533940A (zh) | 治疗晚期实体瘤的方法 | |
| TW202100150A (zh) | 多靶點酪胺酸激酶抑制劑與egfr抑制劑聯合在製備治療腫瘤的藥物中的用途 | |
| JP2005506294A (ja) | テガフル、ウラシル、フォリン酸、パクリタキセルおよびカルボプラチンの投与による腫瘍の治療方法および剤形 | |
| WO2008119260A1 (en) | A medicinal composition of carmustine, preparation method and application | |
| JP2023503167A5 (https=) | ||
| US20240245704A1 (en) | Pharmaceutical composition and use of multi-kinase inhibitor | |
| Lewis et al. | NK1 receptor antagonists and dexamethasone as anticancer agents in vitro and in a model of brain tumours secondary to breast cancer | |
| JP2021511344A5 (https=) | ||
| KR20240158972A (ko) | 소세포 폐암의 치료 방법 | |
| EP3967310B1 (en) | Quinoline derivative and epirubicin used for soft tissue sarcoma combination therapy | |
| TWI598095B (zh) | 治療或緩解高齡或末期癌症患者用之醫藥組合物 | |
| WO2024255214A1 (zh) | 2,3,-环鸟苷酸-核苷酸钠在制备抗肿瘤药物中的用途 | |
| CN1168452C (zh) | 甲氧基吗啉代阿霉素在制备治疗肝肿瘤的药物方面的应用 | |
| RU2024116163A (ru) | Способы лечения рака | |
| MXPA06003841A (es) | Composicion farmaceutica que comprende oxoplatino, las sales y derivados de la misma. | |
| JP2020533368A5 (https=) |